# Curative Efficacy of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM

Study · id `cardio:ct-nct02334969` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02334969](<https://clinicaltrials.gov/study/NCT02334969>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02334969

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2200 participants.

## Technical summary

Registry record NCT02334969. Randomized; double masking; primary purpose prevention. Start 2016-04 (actual); primary completion 2018-08-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 2200 participants (enrolled count; ClinicalTrials.gov record NCT02334969, source copy `cardio:ctgov-nct02334969-2018-11-19`, retrieved 2026-10-26)
- Started: 2016-04 (actual) (ClinicalTrials.gov record NCT02334969, source copy `cardio:ctgov-nct02334969-2018-11-19`, retrieved 2026-10-26)
- Primary completion: 2018-08-30 (actual) (ClinicalTrials.gov record NCT02334969, source copy `cardio:ctgov-nct02334969-2018-11-19`, retrieved 2026-10-26)
- Completion: 2018-08-30 (actual) (ClinicalTrials.gov record NCT02334969, source copy `cardio:ctgov-nct02334969-2018-11-19`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02334969, source copy `cardio:ctgov-nct02334969-2018-11-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02334969-2018-11-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Curative Efficacy of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM
- Condition: Ischemic Stroke
- Intervention (Drug): Naoxintong Capsule
- Intervention (Drug): Placebo
- Lead sponsor: Xiaofei Yu
- Lead sponsor class: OTHER
- Collaborator: Shanghai Municipal Science and Technology Commission
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Naoxintong Capsule for Secondary Prevention of Ischemic Stroke: A Multicenter, Randomized, and Placebo-Controlled Trial (`cardio:pubmed-36251140`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: de7a906b120409eba8a66d7c2639164f0470acac34aca7e5a1247b977d098ee6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
